Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Electron Reports 22-Percent Rise in Q1 Revenue as R&D Spending Grows, Profits Slide

NEW YORK, April 26 (GenomeWeb News) - Thermo Electron today said that first-quarter revenues grew 22 percent as R&D spending rose 6.6 percent and profits contracted 4 percent.


Total receipts for the three months ended April 1 increased to $684 million from $559 million in the first quarter of 2005. The firm attributed the growth to a 30-percent rise in revenue for its life and laboratory sciences segment, which grew to $512 million from $393 million year over year. A 16-percent contribution from acquired businesses also helped drive the growth.


Sales in the firm's measurement and control segment increased 4 percent to $172 million from $166 million, Thermo said.


Thermo said R&D spending increased 6.6 percent in the quarter to $38.7 million from $36.3 million in the comparable period last year.


Net profit in the period contracted 4 percent to $46.9 million, or $.28 per share, from $48.9 million, or $.30 per share, year over. The firm's earnings were hit by $25.6 million, or $.07 per share, in amortization expenses.


The firm finished the first quarter with $230.8 million in cash and cash equivalents.


Thermo officials predicted 2006 revenue of $2.81 billion to $2.86 billion, an increase of 7 percent to 9 percent over 2005 revenue of $2.63 billion, with organic growth of 5 percent to 6 percent for the year.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.